# Open-label Study With Bosentan in Interstitial Lung Disease

> **NCT00319033** · PHASE2,PHASE3 · COMPLETED · sponsor: **Actelion** · enrollment: 132 (—)

## Conditions studied

- Interstitial Lung Disease
- Scleroderma

## Interventions

- **DRUG:** bosentan

## Key facts

- **NCT ID:** NCT00319033
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 132 (—)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00319033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00319033, "Open-label Study With Bosentan in Interstitial Lung Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00319033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*